← All Therapeuticsmd, INC filings

Therapeuticsmd, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
TXMD
Therapeuticsmd, INC
SCHEDULE: Baselake Partners Reports 6.8% Stake in TherapeuticsMD
Baselake Partners, LP, along with its affiliates Baselake Management, LLC and David Paolella, has filed a Schedule 13G, confirming beneficial ownership of 790,703 shares, representing 6.8% of TherapeuticsMD, Inc.'s common stock.
NASDAQ
TXMD
Therapeuticsmd, INC
SCHEDULE: Baselake Partners Acquires 5.2% Stake in TherapeuticsMD
Baselake Partners, LP and associated entities have reported a 5.2% passive ownership stake in TherapeuticsMD, Inc., totaling 607,181 shares.
NASDAQ
TXMD
Therapeuticsmd, INC
SCHEDULE 13G: Clearline Capital Discloses 5.5% Passive Stake in TherapeuticsMD, Inc.
Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a passive 5.5% beneficial ownership stake in TherapeuticsMD, Inc., totaling 635,222 shares as of December 31, 2024.